The challenges and opportunities of a proposed innovative payment model for Advanced Therapy Medicinal Products in Sweden is discussed in a new IHE report.
A hypothetical one-time treatment of ß-thalassemia, that can provide a substantial life-time benefit, is used as an example. The hypothetical example fulfil the two typical challenges for ATMPs; the ”affordability barrier” and “uncertainty of the full value”.